Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL
The non-covalent or reversible Bruton tyrosine kinase (BTK) inhibitor…
Browsing Tag
CLL
No OS Benefit With Ibrutinib in Early-Stage, High-Risk CLL
Patients with early-stage, high-risk chronic lymphocytic leukemia (CLL) failed…
Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader…
Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton’s tyrosine kinase (BTK) mutational…
Bionano Genomics Announces the First Publication Using OGM to Analyze Impact of…
SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to use optical genome mapping (OGM) to analyze the…
Real-World Analysis of Race in CLL Treatment Patterns
At the American Society of Clinical Oncology annual meeting, researchers presented results of a study using…
Zanubrutinib Wins in First-Line CLL for Older Patients
Zanubrutinib (Brukinsa) was superior to chemoimmunotherapy as frontline treatment for older or…
More Data Needed for Treatment Sequencing in CLL
In a recent issue of JCO Oncology Practice, researchers outlined the current first-line management options and…
Novel Ibrutinib Combo Shows High Response Rates in MCL, CLL
Patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) who were treated with…
Durable Remissions in CLL With Fixed-Duration Triplet at 4 Years
Four-year follow-up data from a phase II study evaluating obinutuzumab (Gazyva), ibrutinib (Imbruvica), and…
Biomea Fusion to Present New Preclinical Data Showing BMF-219’s Strong Activity in…
BMF-219 is the first investigational menin inhibitor in clinical development to show potential as a therapeutic agent for CLLBMF-219, a covalent menin inhibitor, demonstrated potency across…